192 related articles for article (PubMed ID: 23806773)
1. Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation.
Hari P; DeFor TE; Vesole DH; Bredeson CN; Burns LJ
Biol Blood Marrow Transplant; 2013 Sep; 19(9):1361-7. PubMed ID: 23806773
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation.
D'Souza AB; Grigg AP; Szer J; Ebeling PR
Intern Med J; 2006 Sep; 36(9):600-3. PubMed ID: 16911552
[TBL] [Abstract][Full Text] [Related]
3. Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients.
Chae YS; Kim JG; Moon JH; Kim SN; Lee SJ; Kim YJ; Sohn SK
Bone Marrow Transplant; 2009 Jul; 44(1):35-41. PubMed ID: 19139732
[TBL] [Abstract][Full Text] [Related]
4. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation.
Tauchmanovà L; Ricci P; Serio B; Lombardi G; Colao A; Rotoli B; Selleri C
J Clin Endocrinol Metab; 2005 Feb; 90(2):627-34. PubMed ID: 15546907
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Ganguly S; Divine CL; Aljitawi OS; Abhyankar S; McGuirk JP; Graves L
Clin Transplant; 2012; 26(3):447-53. PubMed ID: 22003964
[TBL] [Abstract][Full Text] [Related]
6. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.
Otrock ZK; Azar ST; Shamseddeen WA; Habr D; Inati A; Koussa S; Mahfouz RA; Taher AT
Ann Hematol; 2006 Sep; 85(9):605-9. PubMed ID: 16830143
[TBL] [Abstract][Full Text] [Related]
7. Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial.
Huang TW; Wang CJ; Shih HN; Chang Y; Huang KC; Peng KT; Lee MS
BMC Musculoskelet Disord; 2017 May; 18(1):209. PubMed ID: 28532408
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
Kim JE; Ahn JH; Jung KH; Kim SB; Kim HJ; Lee KS; Ro JS; Park YH; Ahn JS; Im YH; Im SA; Lee MH; Kim SY
Breast Cancer Res Treat; 2011 Jan; 125(1):99-106. PubMed ID: 20922564
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.
Westin JR; Thompson MA; Cataldo VD; Fayad LE; Fowler N; Fanale MA; Neelapu S; Samaniego F; Romaguera J; Shah J; McLaughlin P; Pro B; Kwak LW; Sanjorjo P; Murphy WA; Jimenez C; Toth B; Dong W; Hagemeister FB
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):99-105. PubMed ID: 23276888
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial.
Voskaridou E; Anagnostopoulos A; Konstantopoulos K; Stoupa E; Spyropoulou E; Kiamouris C; Terpos E
Haematologica; 2006 Sep; 91(9):1193-202. PubMed ID: 16956818
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia.
Gilfillan CP; Strauss BJ; Rodda CP; Bowden DK; Kean AM; Obaid M; Crawford BA
Calcif Tissue Int; 2006 Sep; 79(3):138-44. PubMed ID: 16969592
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
[TBL] [Abstract][Full Text] [Related]
13. An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial.
Grigg A; Butcher B; Khodr B; Bajel A; Hertzberg M; Patil S; D'Souza AB; Ganly P; Ebeling P; Wong E
Bone Marrow Transplant; 2017 Sep; 52(9):1288-1293. PubMed ID: 28628088
[TBL] [Abstract][Full Text] [Related]
14. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
15. Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study.
Schulte C; Beelen DW; Schaefer UW; Mann K
Osteoporos Int; 2000; 11(4):344-53. PubMed ID: 10928225
[TBL] [Abstract][Full Text] [Related]
16. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
Brufsky AM; Harker WG; Beck JT; Bosserman L; Vogel C; Seidler C; Jin L; Warsi G; Argonza-Aviles E; Hohneker J; Ericson SG; Perez EA
Cancer; 2012 Mar; 118(5):1192-201. PubMed ID: 21987386
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
18. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
Deane A; Constancio L; Fogelman I; Hampson G
BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897
[TBL] [Abstract][Full Text] [Related]
19. Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients.
McClune BL; Polgreen LE; Burmeister LA; Blaes AH; Mulrooney DA; Burns LJ; Majhail NS
Bone Marrow Transplant; 2011 Jan; 46(1):1-9. PubMed ID: 20729922
[TBL] [Abstract][Full Text] [Related]
20. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
